Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis

Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Denosumab and osteoporosis, Kidney

Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: This study investigated the effect of different severities of CKD on bone mineral density (BMD) in patients treated with denosumab.

Methods: This study was a retrospective case review of CKD patients treated with denosumab. Baseline age, sex, and body mass index (BMI) were recorded for all patients. All comorbidities such as diabetes, hypertension, and liver and estimated glomerular filtration rate (eGFR) serum collagen type 1 cross-linked C-telopeptide (CTX) were also recorded. All subjects underwent dual energy X-ray absorptiometry assay of the forearm, lumbar spine, and total hip and femoral neck to determine the BMD. Changes in BMD between baseline and 1 year after denosumab administration were recorded. The correlation between the changes in BMD and eGFR was assessed.

Results: A total 108 patients with CKD who had received denosumab therapy were enrolled. The mean age was 71.04 ± 9.64 years, and 96 patients (88.9%) were women. Baseline eGFR correlated negatively with changes in the BMD of total hip (Rho = 28.7, P=0.01) and femoral neck (Rho = 40.6, P < 0.01) but not those in the spine and forearm. The lower the eGFR, the more was the improvement in BMD in the femoral neck after denosumab therapy. When changes in femoral neck BMD were assessed as outcome measures using linear regression, young patients (p = 0.001) and those with a low eGFR benefitted more from denosumab therapy (p = 0.029).

Conclusion: Denosumab therapy is effective in cases of low eGRF and young age. Aggressive medical attention is needed in these patients.


Table . Association of baseline eGFR and changes in femoral neck bone mineral density after adjusting variables
Variables	Regression coefficient	Standard error	P-value
Gender	0.025	0.023	0.278
Age (years)	-0.004	0.001	0.001
Body mass index (kg/m²)	-0.002	0.002	0.34
Diabetes	-0.018	0.017	0.291
Hypertension	0.01	0.018	0.584
Hyperlipidemia	0.039	0.038	0.308
Liver disease	-0.004	0.021	0.837
Cardiovascular disease	0.015	0.018	0.402
Pulmonary disease	0.025	0.028	0.389
Neurological disease	0.028	0.024	0.25
Baseline CTX	-0.006	0.01	0.578
Baseline eGFR	-0.001	0	0.029
GFR: glomerular filtration rate

Disclosure: Y. C. Chen Sr., None;

To cite this abstract in AMA style:

Chen YC Sr.. Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/changes-in-femoral-neck-bone-mineral-density-inverse-correlate-with-egfr-in-denosumab-treated-osteoporosis-patients-a-hospital-based-analysis/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-femoral-neck-bone-mineral-density-inverse-correlate-with-egfr-in-denosumab-treated-osteoporosis-patients-a-hospital-based-analysis/